A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC

NCT05182944 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: A：non-pCR patients
DRUG: B：non-pCR patients
DRUG: A：pCR patients
DRUG: B：pCR patients

Sponsor

The First Affiliated Hospital of Zhengzhou University